LDS/Medical Tests/DetermaRx for Lung Cancer Disease Management

DetermaRx for Lung Cancer Disease Management

Non-small cell lung cancer (NSCLC) is one of the most frequent cancers and has a relatively poor prognosis and high mortality. Prognosis is most closely related to TNM stage at diagnosis and is significantly impacted by the presence of nodal disease and distant metastases. Based on stage at presentation NSCLC patients are classified as Stage I (18%), Stage II (7%), Stage III (17%) and Stage IV (49%). The 5-year survival rates based on clinical stage at presentation are: Stage I (47%), Stage II (39%), Stage III (27%) and Stage IV (14%). Except for Stage 1A all stages of NSCLC are treated with surgery and chemotherapy or chemoradiation therapy (Stage Ib-Stage IIIb). Chemotherapy generally consists of cisplatin or carboplatin which may be followed with adjuvant immunotherapeutics such as Nivolumab, Atezolizumab, and Osmertinib. Stage IV patients are generally treated systemically.

However, one drawback the conventional staging system is that the differentiation of NSCLC stage IA-IIA patients into the low, intermediate, and high-risk groups is difficult. A new approach involving 14-gene PCR testing, the DetermaRx has been evaluated that may be helpful in categorizing patients into low, intermediate, or high-risk group. This test quantitates the expression of genes: BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A, ESD, TBP, YAP1, and BAG1. Based on the results of the DetermaRx, patients are categorized as high-risk are given adjuvant platinum-duplet chemotherapy to prevent recurrences and increase the chances of disease-free survival.

  • Useful in the categorization of Stage IA-IIA NSCLC patients into low, and high-risk groups to aid treatment decisions

Risk scores are generated based on the gene expression data and the scores are converted into a risk category based on the assays’ cut-off values:

Low-risk
Low risk of recurrence and 5-year mortality; adjuvant chemotherapy not required.

Intermediate-risk:
Moderate risk of recurrence and 5-year mortality; adjuvant chemotherapy might be required.

High-risk
High risk of recurrence and 5-year mortality; adjuvant chemotherapy required.

Reference ranges for risk categories are based on the risk scores generated according to the laboratory’s cut-off values.

Multiplex- Real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), Next Generation Sequencing (NGS).

Specimen: Formalin-fixed paraffin-embedded (FFPE) tissue.

Stability

  • Ambient: 1 week
  • Refrigerated: 1 month
  • Frozen: Unstable
Lung biopsy, EGFR gene mutation analysis, sputum cytology, Arterial blood gas (ABG), squamous cell carcinoma antigen (SSCA), RET (10q11), ROS1 (6q22) rearrangement FISH, BRAF mutation analysis, OncomineDx.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login